Lawmakers Seek Answers on Valeant’s Price Increases

The Wall Street Journal (online registration required): Democrats on the House oversight committee are trying to force Valeant Pharmaceuticals International Inc. to provide documents explaining hefty price increases for two heart drugs.

Valeant shares fell 16.5% to $166.50 Monday following news of the request for a subpoena. The stock had fallen more than 12% over the previous several days amid increasing criticism from law makers about drug-price increases.

Read article